(Press-News.org) DURHAM, N.C. – Cancer cells circulating in the blood carry newly identified proteins that could be screened to improve prognostic tests and suggest targets for therapies, report scientists at the Duke Cancer Institute.
Building on current technologies that detect tumor cells circulating in blood, the Duke team was able to characterize these cells in a new way, illuminating how they may escape from the originating tumors and move to other locations in the body.
The circulating tumor cmoponents include proteins normally seen when embryonic stem cells begin to specialize and move through the body to develop organs such as the heart, bones and skin, the Duke scientists reported this month in the journal Molecular Cancer Research.
The discovery may enhance the accuracy of blood tests that detect circulating cancer cells, giving doctors better information to gauge how a patient's disease is responding or progressing.
"By developing a better blood test based on our findings, we may be able to identify molecular targets for therapy tailored to an individual patient's cancer," said Andrew J. Armstrong, M.D., ScM, assistant professor of medicine at Duke and lead author of the study.
The Duke team isolated tumor cells from blood samples of 57 patients, including 41 men with advanced prostate cancer and 16 women with metastatic breast cancer.
In the tumor cells of more than 80 percent of the prostate cancer patients and 75 percent of those with breast cancer, the researchers detected a group of proteins normally seen during embryonic development when stem cells begin to assume distinct roles.
As stem cells morph to build tissue and organs, they switch back and forth in what is known as epithelial-mesenchymal transition (EMT) and it's opposite, mesencymal-epithelial transition (MET). Cancer cells have that same ability, changing from an epithelial cell similar to the organs from which they arose, to a mesenchymal or connective tissue-like cell. This EMT may underlie much of the treatment resistance and ability of cancer cells to spread.
Current FDA-approved blood tests that detect circulating tumor cells flag molecules associated with epithelial transitions; however, the Duke team found additional markers associated with mesenchymal origins, adding new targets that could be used to enhance the usefulness and sensitivity of the tests.
"Cancer is a hijacking of that normal embryonic stem cell process," Armstrong said. "It reactivates this silent program that is turned off in adult cells, allowing tumor cells to move throughout the body and become resistant to therapy."
Armstrong said the involvement of EMT/MET processes in tumor growth is a relatively new finding that is gaining acceptance among cancer scientists. The discovery by the Duke team adds strong evidence that the EMT/MET processes are underway when a patient's cancer is spreading.
"In my opinion this work presents some of the most compelling data for the existence of epithelial-mesenchymal transitions in human cancer," said Mariano A. Garcia-Blanco, professor of medicine, molecular genetics and microbiology, and senior author in the work.
"This work should pave the way for studies to understand the mechanisms underlying these transitions in humans and their importance in disease progression and therapy," said Garcia-Blanco, who is also director of the Duke Center for RNA Biology.
The Duke team additionally noted that tumor cells appear to be most dangerous when they can easily transition between EMT and MET in a stem cell-like phase of changability that enables them to grow, spread and resist treatment.
That finding could provide new opportunities for novel therapies that target these morphing mechanisms.
"This is not just for a biomarker, it's a direction to take therapies as well," Armstrong said. "It's a new horizon."
###
In addition to Armstrong and Garcia-Blanco, study authors include Matthew S. Marengo; Sebastian Oltean; Gabor Kemeny; Rhonda L. Bitting; James Turnbull; Christina I. Herold; Paul K. Marcom; and Daniel George.
The study was funded with grants from the National Institutes of Health; the Department of Defense Prostate Cancer Research Program; the Prostate Cancer Foundation; the American Cancer Society; and the Duke Cancer Institute.
Armstrong, Oltean, George and Garcia-Blanco have a patent application for the biological process used for detecting the blood markers.
END
Most industry executives, military planners, research managers or venture capitalists charged with assessing the potential of an R&D project probably are familiar with the wry twist on Arthur C. Clarke's third law*: "Any sufficiently advanced technology is indistinguishable from a rigged demo."
After serving for five years as independent evaluators of emerging military technologies nurtured by the Defense Advanced Research Projects Agency (DARPA), a team from the National Institute of Standards and Technology (NIST) shares critical "lessons learned" that can help businesses ...
DIG Coaching Practice presents Attention Talk Radio on the topic of ADHD and college placement. Host Jeff Copper interviews ADHD coach Keith Kosierowski, founder and CEO of Kosierowski Education Group (KEG), who discusses college placement for the teenager with attention deficit hyperactivity disorder (ADHD).
Kosierowski is a certified school counselor with eleven years of experience in both local public and foreign-based schools and has worked at both the American Nicaraguan School and the American International School of Rotterdam as a middle and high school counselor ...
When taken with higher doses of aspirin (more than 300 milligrams), the experimental antiplatelet drug ticagrelor was associated with worse outcomes than the standard drug, clopidogrel, but the opposite was true with lower doses of aspirin.
The study is a secondary analysis of a clinical trial that compared the two drugs and found ticagrelor to be less effective in North America than in other countries.
Researchers suggest the aspirin dose in combination with anti-clotting medicine may alter ticagrelor's effectiveness.
The experimental antiplatelet drug ticagrelor ...
A Clockman Vision Productions is currently packaging O.G. FUNK: TRAINING CAMP. Exec. Producer Kenny Ortega will be presenting the dance-oriented feature drama based on a story by Thomas Guzman Sanchez (urban street dancer/choreographer and film maker). An International search for cast members is now being launched. Using computer technology, anyone can audition in the comfort of their own home for this worldwide search for actors, dancers and skateboarders.
Robert Kubilos will handle directing duties on the screenplay scribed by Guzman Sanchez along with Kubilos. "Kenny ...
For the first time, blood vessels created in the lab from donor skin cells were successfully implanted in patients.
Functioning blood vessels that aren't rejected by the immune system could be used to make durable shunts for kidney dialysis, and potentially to improve treatment for children with heart defects and adults needing coronary or other bypass graft surgery.
For the first time, human blood vessels grown in a laboratory from donor skin cells have been successfully implanted into patients, according to new research presented in the American Heart Association's ...
A team of Yale Cancer Center researchers has confirmed that between 10-20% of breast cancers classified as Estrogen Receptor (ER) negative are really positive. Understanding when and why breast cancers may be misclassified has important implications for treatment and outcomes for women diagnosed with breast cancer. Its findings are published online in the June 28 Journal of Clinical Oncology.
A woman diagnosed with breast cancer can be tested by immunohistochemistry (IHC), a process that detects the presence of specific proteins in cancer tissue. Those who test positive ...
There is a 17% greater risk of dying after a heart attack if you are treated in a hospital located in a U.S. territory—i.e. the U.S. Virgin Islands, Guam, Puerto Rico, American Samoa, and Northern Mariana Islands—rather than in a hospital in the mainland United States, according to new findings published in the Archives of Internal Medicine.
The study by Yale School of Medicine researchers shows that many U.S. citizens who call the U.S. territories home, are at a major healthcare disadvantage.
Led by Marcella Nunez-Smith, M.D., assistant professor at Yale School ...
TURAN SAHINKAYA has joined the board of directors of ReputationDesigner.com, bringing more than twenty years of experience in the technology industry. Turan Sahinkaya has experience in business technology, telecom, internet and marketing and comes with the opinion that people have the right to control and protect their reputation and privacy.
Turan Sahinkaya has worked for some of the world's most recognized industry leaders, as well as several Fortune 100 companies.
Turan Sahinkaya is a graduate of University of California at Berkeley with a Bachelor's Degree in ...
Yale School of Medicine researchers have found that a clinical trial of the epilepsy drug gabapentin may have been a "seeding trial" used by a pharmaceutical company to promote the drug and increase prescriptions, according to a report in the June issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
As described in the study by Yale assistant professor of medicine Joseph Ross, M.D., and his colleagues, a seeding trial is a clinical trial conducted primarily for marketing purposes and intended to promote the drug and increase prescribing by exposing ...
HOUSTON – Forty-five percent of women with advanced breast cancer in the U.S. did not receive postmastectomy radiation therapy (PMRT) despite the publication of evidence-based guidelines outlining PMRT as a potentially lifesaving treatment, according to new research from The University of Texas MD Anderson Cancer Center.
The study, published in the July issue of Cancer, found that PMRT use rates for women with advanced breast cancer have remained static since 1999. According to the research, of the nearly 5,000 women diagnosed with high-risk breast cancer between 1999 ...
